Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Inflammatory Bowel Diseases

Free Subscription Articles published in Scand J Gastroenterol Retrieve available abstracts of 77 articles: HTML format

Single Articles

October 2025
1. CARLSEN A, Steinsbo O, Kvaloy JT, Aabakken L, et al
   Optimizing serum adalimumab levels in maintenance therapy via proactive therapeutic drug monitoring improves markers of disease activity in Crohn's disease.
   Scand J Gastroenterol. 2025 Oct 17:1-12. doi: 10.1080/00365521.2025.2573725.
   PubMed     Abstract available
   
   
   September 2025
2. YE C, Li W, Li X, Jiang Q, et al
   Risk factors for mucosal cytomegalovirus infection and specific endoscopic features in patients with ulcerative colitis.
   Scand J Gastroenterol. 2025 Sep 19:1-11. doi: 10.1080/00365521.2025.2558970.
   PubMed     Abstract available
   
   
   
3. HJELLE H, Myklebust TA, Granlund AVB, Ostvik AE, et al
   Changes in prevalence and incidence of inflammatory bowel disease over 30 years: a population-based cohort study, the HUNT study.
   Scand J Gastroenterol. 2025 Sep 12:1-11. doi: 10.1080/00365521.2025.2555920.
   PubMed     Abstract available
   
   
   
4. HAANAPPEL AEG, van Tieghem de Ten Berghe C, Ali M, Wolthuis AM, et al
   Predictive value of postoperative CRP levels for endoscopic recurrence in patients with Crohn's disease undergoing ileocolic resection.
   Scand J Gastroenterol. 2025 Sep 10:1-9. doi: 10.1080/00365521.2025.2553885.
   PubMed     Abstract available
   
   
   August 2025
5. LIM S, Kim KW, Moon JS, Kim SH, et al
   Tight monitoring with colonoscopy and magnetic resonance enterography improves outcomes in patients with Crohn's disease.
   Scand J Gastroenterol. 2025 Aug 22:1-12. doi: 10.1080/00365521.2025.2544307.
   PubMed     Abstract available
   
   
   
6. BONFILS L, Dalsgaard LT, Poulsen GJ, Eld M, et al
   Validation of date of diagnosis and disease location of inflammatory bowel disease in the Danish National Patient Registry and the Danish Pathology Registry using a regional cohort.
   Scand J Gastroenterol. 2025 Aug 12:1-10. doi: 10.1080/00365521.2025.2544309.
   PubMed     Abstract available
   
   
   
7. MARLICZ W, Skonieczna-Zydecka K, Loniewski I, Koulaouzidis A, et al
   Rethinking iron therapy in IBD: integrating the microbiota perspective.
   Scand J Gastroenterol. 2025;60:817-819.
   PubMed     Abstract available
   
   
   July 2025
8. TAN YY, Cheong EHT, Lim CT, Cai S, et al
   Clinical and environmental impact of intestinal ultrasound for inflammatory bowel disease: a tertiary centre experience in Southeast Asia.
   Scand J Gastroenterol. 2025 Jul 23:1-11. doi: 10.1080/00365521.2025.2533338.
   PubMed     Abstract available
   
   
   
9. LEHMANN V, Bastiaens D, Bosch J, Bennebroek Evertsz F, et al
   Sexual functioning in patients with inflammatory bowel diseases (IBD): prevalence, predictors, and potential benefits of cognitive behavioral therapy (CBT).
   Scand J Gastroenterol. 2025;60:707-715.
   PubMed     Abstract available
   
   
   
10. PETTERSSON N, Kragbjerg F, Hamrin A, Forsblad-d'Elia H, et al
    Spondyloarthritis features in IBD patients: prevalence, referral trends and clinical implications. A questionnaire-based study.
    Scand J Gastroenterol. 2025;60:686-697.
    PubMed     Abstract available
    
    
    June 2025
11. MADSEN GR, Bert K, Wahlin A, Najjar D, et al
    Periodontitis is associated with increased disease activity in a Swedish cohort of patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2025 Jun 14:1-17. doi: 10.1080/00365521.2025.2517217.
    PubMed     Abstract available
    
    
    
12. STRANDE V, Hagen M, Lund C, Asak O, et al
    Predicting severe inflammatory bowel disease: a risk matrix model based on the IBSEN III inception cohort.
    Scand J Gastroenterol. 2025 Jun 8:1-12. doi: 10.1080/00365521.2025.2512591.
    PubMed     Abstract available
    
    
    May 2025
13. NIELSEN MA, Bendix M, Hvas CL, Deleuran B, et al
    Increased mucosal and T-cell expression of 4-1BB and PD-1 are modulated by anti-TNFalpha treatment in Crohn's disease.
    Scand J Gastroenterol. 2025 May 24:1-9. doi: 10.1080/00365521.2025.2505622.
    PubMed     Abstract available
    
    
    
14. DHARMADASA V, Yip Lundstrom LM, Khatibi N, Hossain J, et al
    Factors affecting response rates in patient-reported outcome measures in inflammatory bowel disease.
    Scand J Gastroenterol. 2025 May 10:1-14. doi: 10.1080/00365521.2025.2501070.
    PubMed     Abstract available
    
    
    
15. MAURUD S, Lunde L, Moen A, Opheim R, et al
    Mapping conditional health literacy and digital health literacy in patients with inflammatory bowel disease to optimise availability of digital health information: a cross-sectional study.
    Scand J Gastroenterol. 2025 May 2:1-12. doi: 10.1080/00365521.2025.2497952.
    PubMed     Abstract available
    
    
    
16. TIANEZE DE CASTRO C, da Silva Oliveira D, Freire de Melo F, Lima Barreto M, et al
    Global prevalence of biologic drugs use in inflammatory bowel diseases: a systematic review and meta-analysis.
    Scand J Gastroenterol. 2025;60:439-453.
    PubMed     Abstract available
    
    
    April 2025
17. TUKEK NB, Bakkaloglu OK, Sen G, Hatemi I, et al
    The effects of biologics on ulcerative colitis-related colectomy rate: results of a 22-year study.
    Scand J Gastroenterol. 2025 Apr 29:1-10. doi: 10.1080/00365521.2025.2497954.
    PubMed     Abstract available
    
    
    
18. BROMS G, Forss A, Eriksson J, Askling J, et al
    Adult-onset inflammatory bowel disease and the risk of venous thromboembolism - a Swedish nationwide cohort study 2007-2021.
    Scand J Gastroenterol. 2025 Apr 26:1-10. doi: 10.1080/00365521.2025.2488053.
    PubMed     Abstract available
    
    
    
19. UPADHYAY KG, Desai DC, Ashavaid TF, Dherai AJ, et al
    Evaluating the role of kynurenine/tryptophan ratio as an indicator of disease activity in Indian patients with inflammatory bowel disease. A case-control study.
    Scand J Gastroenterol. 2025 Apr 11:1-9. doi: 10.1080/00365521.2025.2491784.
    PubMed     Abstract available
    
    
    
20. DETLIE TE, Burisch J, Jahnsen J, Bonderup O, et al
    Iron deficiency should not be accepted in patients with inflammatory bowel disease - a Scandinavian expert opinion.
    Scand J Gastroenterol. 2025 Apr 9:1-9. doi: 10.1080/00365521.2025.2487907.
    PubMed     Abstract available
    
    
    March 2025
21. YOUNG JC, Helsingen LM, Refsum E, Hogden A, et al
    Temporal trends in characteristics and management of inflammatory bowel disease.
    Scand J Gastroenterol. 2025 Mar 24:1-9. doi: 10.1080/00365521.2025.2478166.
    PubMed     Abstract available
    
    
    
22. EVERHOV AH, Eberhardson M, Soderling J, Nordenvall C, et al
    Cumulative incidence and prevalence of perianal diseases in patients with inflammatory bowel disease and in the population: a nationwide Swedish study.
    Scand J Gastroenterol. 2025 Mar 17:1-6. doi: 10.1080/00365521.2025.2476669.
    PubMed     Abstract available
    
    
    
23. RASMUSSEN MS, Hansen LO, Deding U, Ellebaek MB, et al
    Applicability of colon capsule endoscopy for monitoring ulcerative colitis: a systematic review.
    Scand J Gastroenterol. 2025 Mar 14:1-7. doi: 10.1080/00365521.2025.2475081.
    PubMed     Abstract available
    
    
    January 2025
24. BERGEMALM D, Baban B, Ljungqvist O, Halfvarson J, et al
    Insulin sensitivity in moderately severe to acute severe ulcerative colitis.
    Scand J Gastroenterol. 2025 Jan 30:1-5. doi: 10.1080/00365521.2025.2459870.
    PubMed     Abstract available
    
    
    
25. RASMUSSEN MH, Brodersen JB, Brasen CL, Madsen JS, et al
    The diagnostic accuracy of plasma and serum calprotectin is inferior to C-reactive protein in patients with suspected Crohn's disease.
    Scand J Gastroenterol. 2025 Jan 29:1-8. doi: 10.1080/00365521.2025.2459236.
    PubMed     Abstract available
    
    
    
26. HAMMER T, Agerbo Modin F, Rubek Nielsen K, Midjord J, et al
    Health-related quality of life at diagnosis and follow-up in Faroese and Danish patients with inflammatory bowel disease - a Faroese IBD cohort study.
    Scand J Gastroenterol. 2025 Jan 17:1-10. doi: 10.1080/00365521.2025.2453429.
    PubMed     Abstract available
    
    
    
27. MUSTONEN A, Rankala R, Voutilainen M, Mattila K, et al
    The impact of IBD on ability to work and study: a patient perspective.
    Scand J Gastroenterol. 2025;60:37-41.
    PubMed     Abstract available
    
    
    November 2024
28. YE YM, Wei MH, Lv KN, Xue XH, et al
    Effects of an anti-inflammatory diet (AID) on maternal and neonatal health outcomes in pregnant Chinese patients with inflammatory bowel disease treated with infliximab (IFX).
    Scand J Gastroenterol. 2024 Nov 9:1-9. doi: 10.1080/00365521.2024.2423828.
    PubMed     Abstract available
    
    
    
29. DRUVEFORS E, Landerholm K, Andersson RE, Sydsjo G, et al
    Reasons for reduced reproduction after colectomy in women with ulcerative colitis.
    Scand J Gastroenterol. 2024 Nov 1:1-8. doi: 10.1080/00365521.2024.2416005.
    PubMed     Abstract available
    
    
    June 2024
30. BONDE CHRISTIANSEN S, Ainsworth MA
    The role of chest X-rays when screening for latent tuberculosis infection in patients with inflammatory bowel disease before starting biologic treatment.
    Scand J Gastroenterol. 2024 Jun 22:1-7. doi: 10.1080/00365521.2024.2368248.
    PubMed     Abstract available
    
    
    May 2024
31. CAMPO M, Hjelle H, Granlund AVB, Sandvik AK, et al
    The relationship between weight change and inflammatory bowel disease. A population-based cohort study, the HUNT study.
    Scand J Gastroenterol. 2024 May 13:1-5. doi: 10.1080/00365521.2024.2353099.
    PubMed     Abstract available
    
    
    
32. HAMMOUDI N, Hassid D, Bonnet J, Tran Minh ML, et al
    Infliximab desensitization in patients with inflammatory bowel diseases: a safe therapeutic alternative.
    Scand J Gastroenterol. 2024;59:553-560.
    PubMed     Abstract available
    
    
    April 2024
33. FORSS A, Flis P, Sotoodeh A, Kapraali M, et al
    Acute interstitial nephritis in patients with inflammatory bowel disease treated with vedolizumab: a systematic review.
    Scand J Gastroenterol. 2024 Apr 29:1-9. doi: 10.1080/00365521.2024.2345383.
    PubMed     Abstract available
    
    
    
34. LARSEN L, Olesen AE, Nayeb AB, Grontved S, et al
    Beyond diagnosis: investigating hospital referral impact on biological treatment initiation, hospital admission, and surgery patterns in inflammatory bowel disease - a Danish population based study.
    Scand J Gastroenterol. 2024 Apr 3:1-8. doi: 10.1080/00365521.2024.2337829.
    PubMed     Abstract available
    
    
    March 2024
35. KIASAT A, Prast-Nielsen S, Rautiainen S, Engstrand L, et al
    Plasma bile acids in association with Crohn's disease.
    Scand J Gastroenterol. 2024 Mar 20:1-9. doi: 10.1080/00365521.2024.2328592.
    PubMed     Abstract available
    
    
    
36. RADFORD SJ, Abdul-Aema B, Tench C, Leighton P, et al
    Substantial cost savings of ultrasound-based management over magnetic resonance imaging-based management in an inflammatory bowel disease service.
    Scand J Gastroenterol. 2024 Mar 19:1-7. doi: 10.1080/00365521.2024.2330588.
    PubMed     Abstract available
    
    
    
37. MERTZ NIELSEN A, Theede K, Gluud LL, Kiszka-Kanowitz M, et al
    Efficacy of optimised thiopurine therapy in patients with moderate-to-severe ulcerative colitis: retrospective long-term follow-up from two randomised trials.
    Scand J Gastroenterol. 2024 Mar 5:1-5. doi: 10.1080/00365521.2024.2323502.
    PubMed     Abstract available
    
    
    
38. VIEUJEAN S, Gillard R, Delanaye P, Seidel L, et al
    Matrix gla protein, a potential marker of tissue remodelling and physiological ageing of the gut in crohn's disease.
    Scand J Gastroenterol. 2024;59:296-303.
    PubMed     Abstract available
    
    
    February 2024
39. MIDJORD J, Nielsen KR, Vang AG, Strom M, et al
    Risk of malignancy in a high-incidence population-based cohort of Faroese patients with inflammatory bowel disease from 1960 to 2020 - a Faroese IBD cohort study.
    Scand J Gastroenterol. 2024 Feb 26:1-8. doi: 10.1080/00365521.2024.2320712.
    PubMed     Abstract available
    
    
    
40. ZEROUGA I, Valeur J, Sommer C, Cvancarova Smastuen M, et al
    Dietary intake and nutritional status in patients with newly diagnosed inflammatory bowel disease: insights from the IBSEN III study.
    Scand J Gastroenterol. 2024 Feb 15:1-9. doi: 10.1080/00365521.2024.2313056.
    PubMed     Abstract available
    
    
    January 2024
41. MALIK S, Loganathan P, Mohan BP
    Letter to editor: effects of vancomycin in primary sclerosing cholangitis with and without inflammatory bowel disease.
    Scand J Gastroenterol. 2024 Jan 30:1-2. doi: 10.1080/00365521.2024.2310168.
    PubMed    
    
    
    
42. THUNBERG J, Granno O, Bergemalm D, Eriksson C, et al
    Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels.
    Scand J Gastroenterol. 2024;59:150-155.
    PubMed     Abstract available
    
    
    December 2023
43. MOLANDER P, Kosunen M, Eronen H, Tillonen J, et al
    Tofacitinib real-world experience in ulcerative colitis in Finland (FinTofUC): a retrospective non-interventional multicenter patient chart data study.
    Scand J Gastroenterol. 2023 Dec 29:1-8. doi: 10.1080/00365521.2023.2298361.
    PubMed     Abstract available
    
    
    
44. STRAATMIJER T, van den Akker-van Marle ME, Ponsioen CY, van der Horst D, et al
    Patient preferences in treatment options of ulcerative colitis: a discrete choice experiment.
    Scand J Gastroenterol. 2023 Dec 2:1-8. doi: 10.1080/00365521.2023.2286191.
    PubMed     Abstract available
    
    
    November 2023
45. HARNO-TASIHIN J, Siregar L, Paajanen M, Arkkila P, et al
    Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses.
    Scand J Gastroenterol. 2023 Nov 25:1-8. doi: 10.1080/00365521.2023.2285229.
    PubMed     Abstract available
    
    
    
46. ZHANG Y, Jiang W, Xu C, Tian J, et al
    The impact of proactive versus reactive drug monitoring of infliximab on treatment outcomes in patients with crohn's disease.
    Scand J Gastroenterol. 2023 Nov 22:1-11. doi: 10.1080/00365521.2023.2283387.
    PubMed     Abstract available
    
    
    
47. ANJIE SI, Hanzel J, Gecse KB, D'Haens GR, et al
    Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies.
    Scand J Gastroenterol. 2023 Nov 14:1-7. doi: 10.1080/00365521.2023.2278424.
    PubMed     Abstract available
    
    
    
48. IBORRA M, Ferreiro-Iglesias R, Maria Dolores MA, Mesonero Gismero F, et al
    Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort.
    Scand J Gastroenterol. 2023 Nov 6:1-9. doi: 10.1080/00365521.2023.2278427.
    PubMed     Abstract available
    
    
    October 2023
49. WANG L, Zhang Y, Wu H, Tang Z, et al
    Intestinal ultrasound score predicts therapeutic outcomes of infliximab in pediatric patients with Crohn's disease.
    Scand J Gastroenterol. 2023 Oct 31:1-8. doi: 10.1080/00365521.2023.2271110.
    PubMed     Abstract available
    
    
    
50. NURMI E, Rantanen A, Paavilainen E, Haapamaki J, et al
    A quality assessment of inflammatory bowel disease nursing care in Finland: a nationwide cross-sectional descriptive study.
    Scand J Gastroenterol. 2023 Oct 30:1-5. doi: 10.1080/00365521.2023.2276654.
    PubMed     Abstract available
    
    
    
51. YAN Q, Feng Z, Jiang B, Yao J, et al
    Biological functions of connexins in the development of inflammatory bowel disease.
    Scand J Gastroenterol. 2023 Oct 14:1-8. doi: 10.1080/00365521.2023.2267713.
    PubMed     Abstract available
    
    
    September 2023
52. FOSSMARK R, Lirhus SS, Hoivik ML
    The impact of proton pump inhibitors on the course of ulcerative colitis: a cohort study of over 10,000 newly diagnosed patients in Norway.
    Scand J Gastroenterol. 2023 Sep 8:1-6. doi: 10.1080/00365521.2023.2255710.
    PubMed     Abstract available
    
    
    August 2023
53. RANKALA R, Mustonen A, Voutilainen M, Mattila K, et al
    Costs of medications used to treat inflammatory bowel disease.
    Scand J Gastroenterol. 2023 Aug 29:1-5. doi: 10.1080/00365521.2023.2248539.
    PubMed     Abstract available
    
    
    
54. ZHANG X, Wang P, Yang Y, Gao X, et al
    Monocyte/macrophage mediates the impact of depression on Crohn's disease.
    Scand J Gastroenterol. 2023 Aug 27:1-11. doi: 10.1080/00365521.2023.2245938.
    PubMed     Abstract available
    
    
    
55. CHEN Y, Sun Z, Li Z, Duan M, et al
    Comparison of endoscopic balloon dilation and surgery for duodenal stricture in patients with Crohn's disease.
    Scand J Gastroenterol. 2023 Aug 25:1-7. doi: 10.1080/00365521.2023.2250495.
    PubMed     Abstract available
    
    
    
56. CHEN C, Lan B, Xie G, Liu Z, et al
    Analysis and identification of ferroptosis-related genes in ulcerative colitis.
    Scand J Gastroenterol. 2023 Aug 2:1-12. doi: 10.1080/00365521.2023.2240927.
    PubMed     Abstract available
    
    
    July 2023
57. KIM J, Jung JH, Jo H, Kim MH, et al
    Risk of uterine cervical cancer in inflammatory bowel disease: a systematic review and meta-analysis.
    Scand J Gastroenterol. 2023 Jul 30:1-10. doi: 10.1080/00365521.2023.2238101.
    PubMed     Abstract available
    
    
    
58. BRODERSEN JB, Jensen MD, Juel MA, Kjeldsen J, et al
    Intestinal ultrasound in patients with suspected Crohn's disease - results of a prospective evaluation by trainees.
    Scand J Gastroenterol. 2023 Jul 17:1-7. doi: 10.1080/00365521.2023.2234538.
    PubMed     Abstract available
    
    
    
59. BARNER-RASMUSSEN N, Sjoblom N, Arola J, Boyd S, et al
    The role of serology, liver function tests and imaging in screening of primary sclerosing cholangitis: the HelPSCreen score.
    Scand J Gastroenterol. 2023 Jul 14:1-8. doi: 10.1080/00365521.2023.2233038.
    PubMed     Abstract available
    
    
    
60. MARK-CHRISTENSEN A, Jolving LR, Anru PL, Murray JA, et al
    A population-based nationwide study on total colectomy for ulcerative colitis and risk of ten prevalent inflammatory or autoimmune diseases.
    Scand J Gastroenterol. 2023 Jul 6:1-7. doi: 10.1080/00365521.2023.2231586.
    PubMed     Abstract available
    
    
    
61. KATO I, Minkevitch J, Sun J
    Oncogenic potential of Campylobacter infection in the gastrointestinal tract: narrative review.
    Scand J Gastroenterol. 2023;58:1453-1465.
    PubMed     Abstract available
    
    
    June 2023
62. BANZRAGCH M, Sanli K, Stensvold CR, Kurt O, et al
    Metabarcoding of colonic cleansing fluid reveals unique bacterial members of mucosal microbiota associated with Inflammatory Bowel Disease.
    Scand J Gastroenterol. 2023 Jun 20:1-11. doi: 10.1080/00365521.2023.2223708.
    PubMed     Abstract available
    
    
    
63. FOLLIN-ARBELET B, Smastuen MC, Hovde O, Jelsness-Jorgensen LP, et al
    Incidence of cancer in patients with ulcerative colitis 30 years after diagnosis (the IBSEN study).
    Scand J Gastroenterol. 2023 Jun 20:1-7. doi: 10.1080/00365521.2023.2223709.
    PubMed     Abstract available
    
    
    
64. KIASAT A, Rautiainen S, Prast-Nielsen S, Engstrand L, et al
    Evaluation of plasma Short chain fatty acid levels as markers for Inflammatory bowel disease.
    Scand J Gastroenterol. 2023 Jun 5:1-7. doi: 10.1080/00365521.2023.2219357.
    PubMed     Abstract available
    
    
    May 2023
65. BEYSENS S, Wellens J, De Hertogh G, Van Laethem A, et al
    Managing metastatic Crohn's disease: a single center experience, review of the current evidence, and treatment algorithm.
    Scand J Gastroenterol. 2023 May 13:1-9. doi: 10.1080/00365521.2023.2209689.
    PubMed     Abstract available
    
    
    
66. KIM KW, Koh SJ, Kang HW, Park H, et al
    Atopic dermatitis is associated with the clinical course of inflammatory bowel disease.
    Scand J Gastroenterol. 2023 May 11:1-7. doi: 10.1080/00365521.2023.2209688.
    PubMed     Abstract available
    
    
    
67. SHI T, Liu W, Li T, Liu H, et al
    HLA-DQ genotype distribution and risk evaluation of celiac disease in Northwest China.
    Scand J Gastroenterol. 2023;58:471-476.
    PubMed     Abstract available
    
    
    April 2023
68. LIU C, Zhan S, Li N, Tu T, et al
    Bile acid alterations associated with indolent course of inflammatory bowel disease.
    Scand J Gastroenterol. 2023 Apr 18:1-10. doi: 10.1080/00365521.2023.2200518.
    PubMed     Abstract available
    
    
    
69. ZHU M, Fan L, Han M, Zhu S, et al
    The usefulness of fecal hemoglobin and calprotectin tests in diagnosing significant bowel diseases: a prospective study.
    Scand J Gastroenterol. 2023;58:368-374.
    PubMed     Abstract available
    
    
    
70. KRIDIN K, Goral D, Shihade W, Tzur-Bitan D, et al
    Vitiligo and Crohn's disease form an autoimmune cluster: insights from a population-based study.
    Scand J Gastroenterol. 2023;58:354-359.
    PubMed     Abstract available
    
    
    March 2023
71. PAUWELS RWM, Ten Bokkel Huinink S, van der Woude CJ, Doukas M, et al
    Early fecal calprotectin levels at week 8 may guide therapeutic decisions on Ustekinumab therapy in patients with Crohn's disease.
    Scand J Gastroenterol. 2023 Mar 27:1-8. doi: 10.1080/00365521.2023.2194009.
    PubMed     Abstract available
    
    
    
72. LIU Y, Ji X, Huang Y, Li Q, et al
    Older patients benefit more from sequential courses of washed microbiota transplantation than younger population with ulcerative colitis.
    Scand J Gastroenterol. 2023 Mar 2:1-10. doi: 10.1080/00365521.2023.2185476.
    PubMed     Abstract available
    
    
    February 2023
73. PAN Y, Huang X, Zhou Z, Yang X, et al
    Clinical significance of a novel uric-acid-based biomarker in the prediction of disease activity and response to infliximab therapy in Crohn's disease.
    Scand J Gastroenterol. 2023 Feb 24:1-7. doi: 10.1080/00365521.2023.2175181.
    PubMed     Abstract available
    
    
    November 2021
74. WANG S, Zhang YR, Yu YB
    The important role of fungi in inflammatory bowel diseases.
    Scand J Gastroenterol. 2021;56:1312-1322.
    PubMed     Abstract available
    
    
    October 2021
75. ALIPOUR O, Lee V, Tejura TK, Wilson ML, et al
    The assessment of sarcopenia using psoas muscle thickness per height is not predictive of post-operative complications in IBD.
    Scand J Gastroenterol. 2021;56:1175-1181.
    PubMed     Abstract available
    
    
    
76. PRIMAS C, Hopf G, Reinisch S, Baumann L, et al
    Role of fecal calprotection in predicting endoscopic recurrence in postoperative Crohn's disease.
    Scand J Gastroenterol. 2021;56:1169-1174.
    PubMed     Abstract available
    
    
    September 2021
77. LI Y, Pan J, Zhou N, Fu D, et al
    A random forest model predicts responses to infliximab in Crohn's disease based on clinical and serological parameters.
    Scand J Gastroenterol. 2021;56:1030-1039.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.